Sarepta Therapeutics Announces Proposed Offering of $375

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
39
Sarepta Therapeutics Announces Proposed Offering of $375 Million of Convertible Senior Notes Due 2024

CAMBRIDGE, MA--(Marketwired - November 07, 2017) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that it intends to offer, subject to market and other conditions, $375 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024. The notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Sarepta also expects to grant the initial purchasers of the notes an option to purchase up to an additional $75 million aggregate principal amount of the notes, solely to cover over-allotments.

Douglas Ingram, Sarepta's president and chief executive officer, has indicated an interest in purchasing approximately $2 million of shares of Sarepta's common stock from certain purchasers of notes in privately negotiated transactions effected through one or more of the initial purchasers of the notes or their respective affiliates, concurrently with the proposed offering. The purchase price per share of the common stock purchased by Mr. Ingram from certain purchasers of notes is expected to equal the closing price per share of Sarepta's common stock on the date of the pricing of the proposed offering.

Sarepta intends to use a portion of the net proceeds from the offering to pay the cost of certain capped call transactions (described below). Sarepta intends to use the remainder of the net proceeds from the offering to strengthen its balance sheet, improve its capital structure and to fund general corporate purposes.

The notes will bear cash interest, payable on May 15 and November 15 of each year, beginning on May 15, 2018. The notes will not be redeemable prior to maturity. The notes will be convertible, only during certain periods and subject to certain circumstances, into cash, shares of Sarepta common stock, or a combination of cash and shares of Sarepta common stock, at Sarepta's election. Final terms of the notes, including interest rate, conversion rate, conversion price, and certain other terms of the offering, will be determined at the time of pricing.

In connection with the pricing of the notes, Sarepta also expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers and/or their respective affiliates and/or other financial institutions (the "option counterparties"). The capped call transactions are expected generally to reduce the potential dilution to Sarepta's common stock upon conversion and/or offset any cash payments Sarepta is required to make in excess of the principal amount of converted notes, as the case may be, of the notes in the event that the market price per share of Sarepta's common stock, as measured under the terms of the capped call transactions, is greater than the strike price of the capped call transactions, which initially corresponds to the conversion price of the notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the notes. If, however, the market price per share of Sarepta's common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, upon conversion of the notes to the extent that such market price exceeds the cap price of the capped call transactions. If the initial purchasers of the notes exercise their over-allotment option, Sarepta expects to enter into additional capped call transactions with the option counterparties.

Sarepta expects that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates will purchase shares of Sarepta's common stock and/or enter into various derivative transactions with respect to Sarepta's common stock concurrently with or shortly after the pricing of the notes. This activity could impact the market price of Sarepta's common stock or the notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to Sarepta's common stock and/or by purchasing or selling Sarepta's common stock or other securities of Sarepta's in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes). This activity could also impact the market price of Sarepta's common stock or the notes, which could affect the ability of holders to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of the notes, it could affect the number of shares of Sarepta's common stock and value of the consideration that holders will receive upon conversion of the notes.

The offer and sale of the notes are not being registered under the Securities Act, or any state securities laws. The notes may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of such jurisdiction.

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.

Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements about the expected terms, timing and size of the proposed offering and capped call transactions, as well as purchases of common stock by Sarepta's president and chief executive officer. These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control, including risks and uncertainties related to market conditions, the expected terms and timing of the proposed offering, the notes and the capped call transactions, the satisfaction of customary closing conditions related to the proposed offering and the risk that Sarepta may not be able to consummate the proposed offering on the anticipated terms, or at all. Applicable risks also include those that are included in the "Risk Factors" section of Sarepta's Quarterly Report on Form 10-Q for the three months ended September 30, 2017, in addition to the risk factors that are included from time to time in Sarepta's subsequent SEC filings. Investors are cautioned not to rely on these forward-looking statements when making an investment decision. Any forward-looking statement in this press release represents Sarepta's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by applicable law. Sarepta's president and chief executive officer has no obligation to purchase any shares of company common stock.

Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid, 212-257-6725 breid@w2ogroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 246

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 53

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 60

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 70

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 77

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 125

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Sable Offshore Investors on Class Action

Updated Category News Views 261

Important Update for Sable Offshore Investors Sable Offshore Corp. (SOC), a prominent player in the oil transportation industry, is currently entangled in legal proceedings that have implications for its investors. If you've invested in SOC and suffered losses exceeding $100,000, there are critical updates you need to be aware of. Details on the Class Action Lawsuit A...

Continue Reading
Polestar Automotive Faces Lawsuit Over Financial Discrepancies

Updated Category News Views 353

Overview of the Legal Situation Concerning Polestar Automotive Recent events have brought attention to Polestar Automotive Holding UK PLC (NASDAQ: PSNY), a company known for its electric vehicles. A securities class action lawsuit has emerged, filed in the United States District Court for the District of New Jersey. This legal action is essential for individuals who...

Continue Reading
Quest Diagnostics' Q3 2024 Performance Boosts Annual Outlook

Updated Category News Views 257

Quest Diagnostics Reports Impressive Q3 2024 Financial Results Quest Diagnostics Incorporated (NYSE: DGX), a top provider of diagnostic information services, has shared its encouraging financial performance for the third quarter ended September 30, 2024. The company saw a notable increase in revenues, reaching $2.49 billion, representing an 8.5% rise compared to the...

Continue Reading
Castle Biosciences Receives NY Health Approval for TissueCypher

Updated Category News Views 118

Castle Biosciences Gains Approval for Revolutionary Test Castle Biosciences, Inc. (NASDAQ: CSTL), based in Friendswood, Texas, is charting a transformative course in healthcare with its recent approval from the New York State Department of Health for its TissueCypher Barrett’s Esophagus test. This achievement marks a significant milestone as TissueCypher stands out as...

Continue Reading
Oryzon Genomics to Conduct Insightful Virtual KOL Event

Updated Category News Views 147

Oryzon Genomics to Host Virtual KOL Event Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), renowned for its innovations in the field of epigenetics, has announced an engaging virtual KOL event aimed at addressing the complexities of Borderline Personality Disorder (BPD). This event, scheduled for a Wednesday at 12:00 pm ET, will be expertly moderated by Dr. Michael...

Continue Reading